Human methylome studies SRP504106 Track Settings
 
Mutant IDH1 inhibition induces reverse transcriptase and dsDNA sensing to activate tumor immunity [human WGBS] [Cholangiocarcinoma]

Track collection: Human methylome studies

+  All tracks in this collection (455)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       PMD       CpG methylation ▾       CpG reads ▾      
Select subtracks by views and experiment:
 All views AMR  PMD  CpG methylation  CpG reads 
experiment
SRX24373100 
SRX24373101 
SRX24373102 
SRX24373103 
SRX24373104 
SRX24373105 
SRX24373106 
SRX24373107 
SRX24373108 
SRX24373109 
SRX24373110 
SRX24373111 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX24373100  CpG methylation  Cholangiocarcinoma / SRX24373100 (CpG methylation)   Schema 
hide
 Configure
 SRX24373101  CpG methylation  Cholangiocarcinoma / SRX24373101 (CpG methylation)   Schema 
hide
 Configure
 SRX24373102  CpG methylation  Cholangiocarcinoma / SRX24373102 (CpG methylation)   Schema 
hide
 Configure
 SRX24373103  CpG methylation  Cholangiocarcinoma / SRX24373103 (CpG methylation)   Schema 
hide
 Configure
 SRX24373104  CpG methylation  Cholangiocarcinoma / SRX24373104 (CpG methylation)   Schema 
hide
 Configure
 SRX24373105  CpG methylation  Cholangiocarcinoma / SRX24373105 (CpG methylation)   Schema 
hide
 Configure
 SRX24373106  CpG methylation  Cholangiocarcinoma / SRX24373106 (CpG methylation)   Schema 
hide
 Configure
 SRX24373107  CpG methylation  Cholangiocarcinoma / SRX24373107 (CpG methylation)   Schema 
hide
 Configure
 SRX24373108  CpG methylation  Cholangiocarcinoma / SRX24373108 (CpG methylation)   Schema 
hide
 Configure
 SRX24373109  CpG methylation  Cholangiocarcinoma / SRX24373109 (CpG methylation)   Schema 
hide
 Configure
 SRX24373110  CpG methylation  Cholangiocarcinoma / SRX24373110 (CpG methylation)   Schema 
hide
 Configure
 SRX24373111  CpG methylation  Cholangiocarcinoma / SRX24373111 (CpG methylation)   Schema 
    

Study title: Mutant IDH1 inhibition induces reverse transcriptase and dsDNA sensing to activate tumor immunity [human WGBS]
SRA: SRP504106
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX24373100 Cholangiocarcinoma 0.636 12.2 76305 12411.0 801 1002.6 4921 224593.2 0.984 title: GSM8230087 WGBS, SNU1079 in vitro, DMSO, Replicate 1, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: DMSO; geo_loc_name: missing; collection_date: missing
SRX24373101 Cholangiocarcinoma 0.634 13.2 78022 12224.5 928 999.1 4943 223911.7 0.985 title: GSM8230088 WGBS, SNU1079 in vitro, DMSO, Replicate 2, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: DMSO; geo_loc_name: missing; collection_date: missing
SRX24373102 Cholangiocarcinoma 0.634 12.8 77577 12266.8 875 1005.9 4930 224360.2 0.985 title: GSM8230089 WGBS, SNU1079 in vitro, DMSO, Replicate 3, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: DMSO; geo_loc_name: missing; collection_date: missing
SRX24373103 Cholangiocarcinoma 0.637 12.1 77003 12308.1 790 992.9 4868 226831.7 0.984 title: GSM8230090 WGBS, SNU1079 in vitro, IFNg, Replicate 1, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: IFNg; geo_loc_name: missing; collection_date: missing
SRX24373104 Cholangiocarcinoma 0.636 13.1 78107 12170.9 882 1011.3 4898 225898.6 0.984 title: GSM8230091 WGBS, SNU1079 in vitro, IFNg, Replicate 2, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: IFNg; geo_loc_name: missing; collection_date: missing
SRX24373105 Cholangiocarcinoma 0.635 12.4 77139 12287.5 873 1016.1 4894 225670.4 0.985 title: GSM8230092 WGBS, SNU1079 in vitro, IFNg, Replicate 3, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: IFNg; geo_loc_name: missing; collection_date: missing
SRX24373106 Cholangiocarcinoma 0.526 12.3 70065 12218.0 3907 992.4 4793 208493.3 0.985 title: GSM8230093 WGBS, SNU1079 in vitro, AG120, Replicate 1, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: AG120; geo_loc_name: missing; collection_date: missing
SRX24373107 Cholangiocarcinoma 0.525 12.4 70625 12136.9 3965 981.4 4737 210648.5 0.986 title: GSM8230094 WGBS, SNU1079 in vitro, AG120, Replicate 2, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: AG120; geo_loc_name: missing; collection_date: missing
SRX24373108 Cholangiocarcinoma 0.529 12.4 70865 12117.2 3969 976.4 4746 210026.9 0.985 title: GSM8230095 WGBS, SNU1079 in vitro, AG120, Replicate 3, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: AG120; geo_loc_name: missing; collection_date: missing
SRX24373109 Cholangiocarcinoma 0.460 11.6 66366 12788.3 9951 1058.5 4639 209510.6 0.986 title: GSM8230096 WGBS, SNU1079 in vitro, AG120+IFNg, Replicate 1, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: AG120 + IFNg; geo_loc_name: missing; collection_date: missing
SRX24373110 Cholangiocarcinoma 0.465 11.4 66309 12806.2 10216 1062.2 4608 210372.5 0.986 title: GSM8230097 WGBS, SNU1079 in vitro, AG120+IFNg, Replicate 2, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: AG120 + IFNg; geo_loc_name: missing; collection_date: missing
SRX24373111 Cholangiocarcinoma 0.463 11.9 67404 12537.6 14496 1140.9 3588 274645.8 0.984 title: GSM8230098 WGBS, SNU1079 in vitro, AG120+IFNg, Replicate 3, Homo sapiens, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: SNU1079; cell_type: tumor cells; genotype: Known IDH1R132C, CDKN2A.del, PBRM1.fs; treatment: AG120 + IFNg; geo_loc_name: missing; collection_date: missing

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.